Comparative Pharmacology
Head-to-head clinical analysis: AURLUMYN versus CLOLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURLUMYN versus CLOLAR.
AURLUMYN vs CLOLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with CrCl <60 mL/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent